Alderyx.

Ardelyx GAAP EPS of -$0.13 misses by $0.03, revenue of $11.4M beats by $0.99M; Ardelyx resubmits NDA to FDA for tenapanor for chronic kidney disease; Ardelyx adds 16% as Wedbush upgrades after Q4 ...Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart ...Ardelyx received approval for IBSRELA (tenapanor) with plans to launch in the second quarter of 2022. Ardelyx is developing tenapanor, a novel product candidate to control serum phosphorus in ...According to 6 stock analysts, the average 12-month stock price forecast for Ardelyx stock is $8.58, which predicts an increase of 98.15%. The lowest target is $7.00 and the highest is $11. On average, analysts rate Ardelyx stock as a strong buy.Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD.

Under the terms of the agreement, Ardelyx will receive an upfront payment of $12 million and is eligible to receive additional milestones of up to $113 million, as well as tiered royalty payments on net sales ranging from the mid-teens to 20 percent.Fosun Pharma will have the exclusive rights to market and sell tenapanor in China. "As one of …Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart ...... Alderyx · Fantasy Girls Love. Its yuri. #182 There Is No Secret Slime Level. (5). Views: 2.8k, Favorites: 50, Chapters: 11, Chapters/Week: 0, Readers: 60 ...

Oct 25, 2021 · ARDX now has a market cap of $122mn, a cash reserve of $141mn as of end-September, and a debt of $65mn. Short interest stands at 8.7%. Research and development expenses were $26.0 million for the ... Ardelyx is also advancing RDX013, a potassium secretagogue, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and has an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD.

Ardelyx is also advancing RDX013, a potassium secretagogue, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart ...ARDX has a current market cap of $95mn against a debt of $65mn and cash of $141mn. The company earned $1.2mn of collaboration revenue in the September quarter. R&D expenses were $23.7mn, a small ...Ardelyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelyx's business in general, please refer to Ardelyx's Quarterly Report ...The company will host a conference call today, November 3, 2022, at 4:30 p.m. ET to review its financial results and provide a business overview. To participate in the conference call, please dial ...

Stock analysis for Ardelyx Inc (ARDX:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Ardelyx is also advancing RDX013, a potassium secretagogue, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart ...

Sep 3, 2021 · Ardelyx is focused on discovering, developing and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. Ardelyx is developing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 ... Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults. Download PDF. IBSRELA®(tenapanor) is the First and Only NHE3 …Ardelyx is focused on discovering, developing, and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. Ardelyx is advancing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, for which the company submitted an NDA to the ...Dec 31, 2022 · Ardelyx’s first approved product, IBSRELA® (tenapanor) is available in the United States and Canada. Ardelyx is developing XPHOZAH® (tenapanor), a novel product candidate for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis, which has completed three successful Phase 3 trials. WALTHAM, Mass., Feb. 28, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today reported business events and financial results for the fourth quarter and full year …Ardelyx has an Altman Z-Score of 2.99 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for Ardelyx, Inc. (ARDX) stock, including valuation metrics, financial numbers, share information and more.... Alderyx · Fantasy Girls Love. Its yuri. #182 There Is No Secret Slime Level. (5). Views: 2.8k, Favorites: 50, Chapters: 11, Chapters/Week: 0, Readers: 60 ...

Ardelyx is a publicly-traded commercial biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet ...Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. -51.50M. -247.86%. Get the latest Alteryx Inc (AYX) real-time quote, historical ...Welcome to Ardelyx Grants and Giving. This site is intended to be used for submitting requests for support of: Educational Programs: Support for clinical, technical, and scientific education programs or activities focused on the therapeutic area and disease states addressed by our products, including grants to funding for educational conferences, …Ardelyx had sales team, launch plan ready to go before dialysis drug approval Ardelyx Inc. CEO Mike Raab was pretty confident that his company's dialysis drug would be approved. By the time the U.S. Food and Drug Administration handed down its decision late Tuesday, Waltham-based Ardelyx had already hired around 60 salespeople.Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases.The company expects that the workforce reduction will decrease its annual cash compensation costs by approximately $18.1 million. At the end of the third quarter ended September 30, 2021, Ardelyx ...

Ardelyx is focused on discovering, developing and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. Ardelyx is advancing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, for which the company's NDA …

Follow. WALTHAM, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first ...The average one-year price target for Ardelyx (NASDAQ:ARDX) has been revised to 9.84 / share. This is an increase of 6.30% from the prior estimate of 9.25 dated …Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among …Ardelyx received approval for IBSRELA (tenapanor) with plans to launch in the second quarter of 2022. Ardelyx is developing tenapanor, a novel product candidate to control serum phosphorus in ...Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. The Company's product pipeline includes IBSRELA (tenapanor), XPHOZAH, RDX013 Program, and RDX020 Program.SCIENCE & PIPELINE - Ardelyx. For decades, the gut had been under-recognized as a viable site for new therapeutic points of intervention for treating disease. Using our discovery model, which recreates environments within certain areas of the gastrointestinal tract and kidney, Ardelyx® scientists have been able to elucidate new and previously ... 900.00%. Regeneron Pharmaceuticals Inc. -0.16%. $87.19B. ALDX | Complete Aldeyra Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial ...Sep 30, 2022 · Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD.

Ardelyx is also advancing RDX013, a potassium secretagogue, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and has an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients

As part of its response to Ardelyx's appeal of the Complete Response Letter received on July 28, 2021, the FDA's Office of New Drugs (OND) stated that additional input from an Advisory Committee, including the addition of input from expert clinicians who care for patients on dialysis, would be valuable in further considering the clinical meaningfulness of the phosphate lowering effect observed ...

WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. The Company's product pipeline includes IBSRELA (tenapanor), XPHOZAH, RDX013 Program, and RDX020 Program. Tenapanor is a small molecule …Ardelyx received a Complete Response Letter from the U.S. FDA for its Tenapanor drug. Check out why I believe ARDX stock is a very risky bet right now.Summary. Ardelyx shows strong financial health, underpinned by 61% QoQ growth in flagship product Ibsrela and an 18-month cash runway. Japanese approval of tenapanor is a pivotal catalyst ...WALTHAM, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults. Download PDF. IBSRELA®(tenapanor) is the First and Only NHE3 …Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States , IBSRELA ® (tenapanor) and XPHOZAH ® (tenapanor) as well as early-stage pipeline candidates.Oct 25, 2021 · ARDX now has a market cap of $122mn, a cash reserve of $141mn as of end-September, and a debt of $65mn. Short interest stands at 8.7%. Research and development expenses were $26.0 million for the ... Alteryx for Good Program Overview. 05-17-2023 01:59 PM Created ‎05-17-2023 01:58 PM. We believe in supporting the communities where we live and work, striving to be a place where you can bring your authentic self to work, and are committed to reducing our environmental impact. Alteryx for Good is a key part of this, leading the social impact ...This acceptance triggers a $2 million milestone payment to Ardelyx under the terms of the license agreement between Ardelyx and its collaboration partner in China, Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (Fosun Pharma). A potential approval of the NDA submission in China is expected by the end of 2024.Oct 13, 2021. Ardelyx Inc. plans to lay off another 102 people — on top of 83 employees it decided to cut loose in August — after regulators this summer blocked approval of the company's drug ...Discover historical prices for ARDX stock on Yahoo Finance. View daily, weekly or monthly format back to when Ardelyx, Inc. stock was issued.

SCIENCE & PIPELINE - Ardelyx. For decades, the gut had been under-recognized as a viable site for new therapeutic points of intervention for treating disease. Using our discovery model, which recreates environments within certain areas of the gastrointestinal tract and kidney, Ardelyx® scientists have been able to elucidate new and previously ...As follows, Ardelyx procured $2.5M in total revenues compared to $1.3M for the same period a year prior. Of that figure, $1.5M accounts for total product sales.Ardelyx, Inc. (NASDAQ:ARDX) Q3 2023 Earnings Call Transcript October 31, 2023 Ardelyx, Inc. beats earnings expectations. Reported EPS is $0.02909, expectations were $-0.11. Operator: Good day and welcome to the Ardelyx Third Quarter 2023 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded. I …Instagram:https://instagram. mutual fund account vs brokerage accountcanoo atockrailway stocksotc stocks on robinhood As of last trade Ardelyx Inc (ARDX:NMQ) traded at 3.61, -29.66% below its 52-week high of 5.13, set on Apr 17, 2023. Data delayed at least 15 minutes, as of Nov 13 2023 16:15 GMT. Latest Ardelyx Inc (ARDX:NMQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.Alteryx For Good Program Qualifications. 06-29-2021 05:51 PM Created ‎04-28-2020 07:03 PM. The Alteryx for Good program was designed for students, educators, and nonprofit organizations around the world starting out on their analytics journey have access to the skills and resources they need to develop an in-demand skillset that … best day trading coursesrussell 3000 etf Ardelyx has a Phase 2 potassium lowering compound, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among …About Ardelyx, Inc. Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. nysearca voov View the latest Ardelyx Inc. (ARDX) stock price, news, historical charts, analyst ratings and financial information from WSJ.Alteryx - Democratizing Automation. Alteryx Gallery helps store and execute workflows and analytical apps shared across multiple business groups seamlessly. Alteryx is one of the …